Previous studies have reported that SFRP1 promoter hypermethylation could serve as an epigenetic biomarker for cancer detection, progression and prognosis for breast and colorectal carcinomas [16, 17]. This evidence concerns the gene SFRP1 and colorectal carcinoma.